<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  

Dadun > Depósito Académico > Facultad de Farmacia > Departamento de Farmacia y Tecnología Farmacéutica > DA - Farmacia - Tecnología Farmacéutica - Artículos de revista >

Modeling of the In Vivo Antinociceptive Interaction between an Opioid Agonist, (+)-O-Desmethyltramadol, and a Monoamine Reuptake Inhibitor, (—)-O-Desmethyltramadol, in Rats
Autor(es) : Garrido, M.J. (María Jesús)
Valle, M. (Marta)
Campanero, M.A. (Miguel Angel)
Calvo, R. (Rosario)
Troconiz, I.F. (Iñaki F.)
Palabras clave : Antinociception
Pk-pd model
Fecha incorporación: 2000
Editorial : Williams & Wilkins
Versión del editor: http://dx.doi.org/10.1124/jpet.102.047779
ISSN: 0022-3565
Cita: Garrido MJ, Valle M, Campanero MA, Calvo R, Trocóniz IF. Modeling of the In Vivo Antinociceptive Interaction between an Opioid Agonist, (+)-O-Desmethyltramadol, and a Monoamine Reuptake Inhibitor, (—)-O-Desmethyltramadol, in Rats. J Pharmacol Exp Ther. 2000 Oct;295(1):352-9.
The pharmacokinetic-pharmacodynamic (pk-pd) characterization of the in vivo antinociceptive interaction between (+)-O-desmethyltramadol [(+)-M1] and (-)-O-desmethyltramadol [(-)-M1], main metabolites of tramadol, was studied in three groups of rats. (+)-M1 and (-)-M1, both with different pd properties, were studied under steady-state and nonsteady-state conditions, depending on the group. Plasma drug concentration and antinociception were simultaneously measured in each animal by using an enantioselective analytical assay and the tail-flick test, respectively. Respiratory depression also was evaluated in another series of experiments according to the same experimental conditions. The pk behavior was similar for both enantiomers and no significant (P >.05) interaction between two compounds was found at this level. However, a significant (P <.01) potentiation in the antinociceptive effect elicited by (+)-M1 was found during and after (-)-M1 administration. The pd model used to describe the time course of the antinociception in the presence of (+)-M1, (-)-M1, or both is based on previous knowledge of the compounds and includes the following: 1) an effect compartment model to account for the opioid effect of (+)-M1, and 2) an indirect response model accounting for the release of noradrenaline (NA) caused by (+)-M1, and the inhibition of the NA reuptake due to the action of (-)-M1. The model predicts a positive contribution to antinociception of the predicted increasing levels of NA. No significant (P >.05) respiratory effects were seen during or after (+)-M1 and (-)-M1 administration.
Enlace permanente: http://hdl.handle.net/10171/21763
Aparece en las colecciones: DA - CUN - Farmacología clínica - Artículos de revista
DA - Farmacia - Tecnología Farmacéutica - Artículos de revista

Ficheros en este registro:
Fichero:  JPharmExpTher2000Modeling.pdf
Tamaño:  391,57 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.